BenzingaOctober 23, 2026 at 4:24 AM NY4 Days Ago
Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $34 to $22.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
